Level C· Early human research exploring benefitsRetrospective StudyEurope PMC

Periorbital Changes Following Glucagon-Like Peptide-1 Receptor Agonist Use: A Retrospective Cohort Study of Oculofacial Complications and Interventions

Saffari PS., Davila N., Pradeep T., Wong B., Lee WW.

Retrospective Study on Type 2 Diabetes, Skin Aging, published in Ophthalmic Plast Reconstr Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Ophthalmic Plast Reconstr Surg (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41251628
PMCID
PMC12743635
DOI
10.1097/iop.0000000000003129

Abstract (original English)

Purpose The purpose of this study is to evaluate whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with periorbital changes in patients with type 2 diabetes mellitus (T2DM) or obesity. Methods A retrospective cohort study was conducted using the TriNetX Research Network database. Patients with T2DM treated with insulin or other antidiabetic agents and who were GLP-1RA naive served as the T2DM control group. The obesity control group included patients with obesity (body mass index ≥30 kg/m 2 ) who neither had bariatric surgery nor T2DM and were GLP-1RA naive. Study groups included patients with T2DM or obesity treated with GLP-1RAs. Rates of blepharoptosis, brow ptosis, dermatochalasis, ectropion, and entropion were recorded alongside their respective rates of surgical repair as well as the frequency of rhytidectomy and botulinum A toxin use. Outcomes were assessed at 3 and 20 years postdrug approval for the obesity and T2DM study groups, respectively. Results Patients with T2DM using any GLP-1RA were significantly more likely to develop brow ptosis ( p Conclusions GLP-1RA use by patients with obesity or T2DM resulted in significant periorbital changes and subsequent repair. When compared to their respective controls, patients using GLP-1RAs for obesity observed more periorbital changes than those with TD2M, likely secondary to excess adipose

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansBlepharoptosisDiabetes Mellitus, Type 2ObesityHypoglycemic AgentsRhytidoplastyRetrospective StudiesAgedMiddle AgedFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research